Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States.
Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States.
ACS Chem Biol. 2024 Nov 15;19(11):2268-2276. doi: 10.1021/acschembio.4c00505. Epub 2024 Oct 14.
Synthetic genome readers/regulators (SynGRs) are bifunctional molecules that are rationally designed to bind specific genomic sequences and engage cellular machinery that regulates the expression of targeted genes. The prototypical SynGR1 targets GAA trinucleotide repeats and recruits the BET family of transcriptional regulatory proteins via a flexibly tethered ligand, JQ1. This pan-BET ligand binds both tandem bromodomains of BET proteins (BD1 and BD2). Second-generation SynGRs, which substituted JQ1 with bromodomain-selective ligands, unexpectedly revealed that BD1-selective ligands failed to functionally engage BET proteins in living cells despite displaying the ability to bind BD1 in vitro. Mechanistically, recruiting a BET protein via BD1- or BD2-selective SynGRs should have resulted in indistinguishable functional outcomes. Here we report the conversion of inactive BD1-targeting SynGRs into functional gene regulators by a structure-guided redesign of the chemical linker that bridges the DNA-binding molecule to the highly selective BD1 ligand GSK778. The results point to an optimal zone for positioning the BD1-selective ligand for functional engagement of BET proteins on chromatin, consistent with the preferred binding of BD1 domains to distal acetyllysine residues on histone tails. The results not only resolve the mechanistic conundrum but also provide insight into domain-selective targeting and nuanced design of chemo probes and therapeutics.
合成基因组读取器/调节剂(SynGRs)是一种双功能分子,经过合理设计可与特定基因组序列结合,并激活细胞机制来调节靶向基因的表达。原型 SynGR1 靶向 GAA 三核苷酸重复序列,并通过柔性连接的配体 JQ1 招募 BET 家族转录调节蛋白。这种泛 BET 配体结合 BET 蛋白的两个串联溴结构域(BD1 和 BD2)。第二代 SynGRs 用溴结构域选择性配体替代了 JQ1,但出乎意料的是,尽管第二代 SynGRs 具有体外结合 BD1 的能力,但它们的 BD1 选择性配体在活细胞中未能有效地与 BET 蛋白结合。从机制上讲,通过 BD1 或 BD2 选择性 SynGR 招募 BET 蛋白应该会产生相同的功能结果。在这里,我们通过对连接 DNA 结合分子和高度选择性 BD1 配体 GSK778 的化学连接子进行结构指导重新设计,将无活性的 BD1 靶向 SynGR 转化为功能性基因调节剂。结果表明,BD1 选择性配体在染色质上与 BET 蛋白进行功能结合的最佳位置,与 BD1 结构域与组蛋白尾部远端乙酰赖氨酸残基的优先结合一致。该结果不仅解决了机制难题,还为化学探针和治疗剂的结构域选择性靶向和细微设计提供了新的思路。